Oncology Competitor Counter-Detail Builder
Generate evidence-based competitive rebuttals for oncology sales conversations instantly.
What You Can Do
You can rapidly construct evidence-based competitive responses that address specific oncologist objections with clinical parity analysis, head-to-head trial comparisons, and safety contextualization. The skill generates 2-3 minute talking points that distinguish your oncology drug on meaningful endpoints while flagging claims requiring medical science liaison support or printed evidence—ensuring your counter-details hold up to regulatory scrutiny without crossing into prohibited promotional territory.
Features
Side-by-side comparison of your drug versus competitor on efficacy endpoints, progression-free survival, overall survival, and response rates for specific patient populations
Automatic flagging of claims requiring medical science liaison escalation, printed evidence support, or REMS documentation before delivery
Identifies which patient subgroups benefit most from your drug and which may be better served by competitor options, supporting ethical positioning
Frames efficacy within the unique safety monitoring, pharmacovigilance, and access requirements of your drug versus competitor alternatives
Structures rebuttals around published pivotal trials, real-world evidence studies, and guideline positioning with specific data point citations
Generates speaking points for competitive scenarios in multi-specialty team settings with oncologist, pathologist, and other stakeholder objections pre-addressed
Incorporates post-market effectiveness data, observational studies, and registry data to support efficacy claims beyond pivotal trial populations
Example Output
Example 1 — Response to KEYNOTE Trial Objection
Doctor says: "Your competitor's KEYNOTE study showed a 40% response rate. Yours was only 32%."
Your counter-detail: "The KEYNOTE population was PD-L1 positive, high-burden disease. In our head-to-head Phase 3 subgroup of PD-L1 positive patients, response rates were comparable at 38%, but our median progression-free survival was 14.2 months versus 11.8 months in their data. Plus, their REMS program requires monthly imaging for safety monitoring—our protocol allows quarterly assessments once stable, which improves real-world adherence."
Example 2 — REMS Complexity Objection
Doctor says: "Your competitor's REMS is simpler. We're thinking of switching."
Your counter-detail: "I understand—REMS burden matters to your infusion center. Ours does require baseline and periodic liver monitoring, but that overlaps with standard care panels for oncology patients anyway. What's different: our real-world data from 2,400 patients showed 94% completion rates because monitoring integrated into routine labs. Their simpler REMS reflects a different safety profile—more baseline hepatotoxicity events in trials. Happy to connect our medical science team to review your specific workflow and see where we can streamline."
Example 3 — Patient Population Qualifier
Doctor says: "Should I use your drug or their drug for this BRCA-wild-type patient?"
Your counter-detail: "Great question. For BRCA-wild-type patients, our data shows best benefit in those with high mutational burden—median OS benefit is 5.2 months. Their drug showed stronger benefit in BRCA-mutant patients, around 7 months OS improvement. For your specific patient, I'd actually lean toward their option based on the tumor profile we discussed. But if you see a high-burden wild-type patient next, ours typically outperforms in our real-world cohort."
What's Included
- SKILL.md instruction file: Complete framework for structuring competitive responses with compliance checkpoints
- Clinical parity comparison template: Side-by-side trial data structure for efficacy, safety, and REMS comparison
- Compliance guardrail checklist: Flags claims requiring MSL escalation, printed evidence, or additional regulatory support
- Patient population qualifier workflow: Decision tree for identifying which patient subgroups fit your drug versus competitor alternatives
- Tumor board talking point template: Pre-built responses for common multi-specialty objections with citations
Who It's For
- Oncology field sales representatives responding to real-time competitive objections during office visits
- Regional or territory managers preparing account teams for high-risk accounts with competitor market share
- Inside sales specialists supporting external reps with rapid competitive intelligence during Zoom or phone calls
- Medical science liaisons briefing field teams before tumor board presentations or clinical advisory board meetings
- New oncology reps building confidence in competitive positioning during early-career ramp
Best For
- Real-time competitive rebuttals during oncologist objections in office or virtual settings
- Pre-visit account planning for known competitive threats or switching risk
- Tumor board preparation where multiple competing drugs will be discussed
- Published trial or guideline objection responses requiring clinical evidence grounding
- Patient population qualification conversations to identify best-fit candidates for your drug
You might also like
You can rapidly map the clinical, pharmacy, and procurement decision-makers at target hospital systems, assemble persuasive health economic and clinical evidence tailored to each stakeholder's priorities, and develop presentation strategies that address objections before committee meetings occur. This skill compresses typical 6+ month formulary cycles into 2-3 meeting cycles by organizing evidence strategically and anticipating pharmacoeconomic scrutiny.
by killvault
Transform scattered clinical research into structured, evidence-based summaries tailored for healthcare decision-making. This skill automatically assesses study quality, evaluates potential biases, and grades the strength of evidence using standardized frameworks like GRADE. You get synthesis ready to inform clinical decisions, guideline updates, or research protocols—all with transparent reasoning about confidence levels and limitations.
by killvault
Consolidate information from multiple research sources into polished, structured intelligence reports optimized for C-suite decision-making. You provide raw research, URLs, documents, or topics—Claude synthesizes findings into executive summaries, market analysis, competitive insights, and strategic recommendations with full source attribution.
by killvault
Create professional institutional policies, detailed finding aids, accession records, and collection management documentation tailored to your special collections. You'll produce compliance-ready policies, descriptive guides that improve discoverability, and standardized documentation frameworks that streamline collection administration.
by killvault
Gather competitive intelligence from multiple sources and transform it into structured executive briefings. You'll receive verified, cited analysis that highlights competitive positioning, market threats, and strategic opportunities. The skill organizes findings into polished, decision-ready formats complete with source attribution and actionable insights.
by killvault
This skill helps you design robust metadata schemas for library and archival digitization projects, validate collections against preservation standards like PREMIS and Dublin Core, and create compliance documentation to ensure your digital assets meet long-term preservation requirements. You get detailed gap analysis, preservation risk assessments, and actionable remediation plans for any stage of digitization workflow.
by killvault
This skill helps you create comprehensive collection development policies, design acquisitions frameworks, and identify collection gaps for special collections and archives. You can generate professional policy documents, gap analysis reports, and acquisition decision matrices tailored to your institution's mission and collecting scope. It produces institutional-grade frameworks that guide collection building, vendor relationships, and resource allocation for years to come.
by killvault
You build comprehensive scientific briefs that transform reactive Q&A into proactive narrative leadership. This skill helps you layer evidence from mechanism of action through clinical endpoints to real-world outcomes, while mapping anticipated objections and preparing response frameworks that preserve credibility in high-stakes HCP conversations. You'll structure interactions with key opinion leaders, advisory boards, and research groups with the scientific rigor they expect.
by killvault